Presentations Include Proof-of-Concept Animal Data on Previously Disclosed Fusion Protein TT30 and New Molecules TT32 and mAb171
CAMBRIDGE, Mass., Sept. 25 /PRNewswire/ -- Taligen Therapeutics Inc. today announced that data from in vivo disease models on several of the company's pipeline candidates will be presented next week at the XXII International Complement Workshop in Basel, Switzerland.
The data, which will be presented in eight oral and poster presentations, are the results of research conducted by the laboratories of Michael Holers, M.D., chief scientific officer of Taligen, and the company's academic collaborators in the complement research community. Five studies testing the company's fusion protein TT30 and two new compounds, a fusion protein TT32 and a monoclonal antibody mAb171, in animal models are highlighted below. These data further support Taligen's approach that targeting the alternative complement pathway can impact complement-mediated inflammatory disease processes.
Targeted inhibition of the alternative pathway by CR2-fH fusion protein ameliorates progression of renal disease in MRL/lpr mice
Hideharu Sekine*, Gary Gilkeson, Stephen Tomlinson
Oct. 1, 2008, Posters - 10:30 a.m. - noon, Session 2, Poster 174
Alternative complement pathway signaling in a mouse model of choroidal neovascularisation
Barbel Rohrer*, Qin Long, Brooks Wilson, Beth Coughlin, Yuxiang Huang, Fei Qiao, Peter Tang, Kannan Kunchithapautham, Gary Gilkeson, Stephen Tomlinson
Oct. 1, 2008, Posters - 10:30 a.m. - noon, Session 2, Poster 202
TT30 and TT32
Targeted complement-inhibitory proteins CR2-Crry and CR2-fH ameliorate allergen-induced airway hyperresponsiveness and inflammation
Joshua Thurman*, Katsuyuki Takeda, Stephen Tomlinson, Erwin Gelfand, V. Michael Holers
Oct. 1, 2008, Posters - 10:30 a.m. - noon, Session 2, Poster 171
|SOURCE Taligen Therapeutics Inc.|
Copyright©2008 PR Newswire.
All rights reserved